Movatterモバイル変換

Vipadenant

From Wikipedia, the free encyclopedia

Pharmaceutical compound

Vipadenant
Clinical data

Other names	BG-14; BG14; BIIB-014; BIIB014; BIIB14; CEB-4520; V-2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; VR-2006
Routes of administration	Oral^[1]
Drug class	Adenosine A_2A receptor antagonist;Antiparkinsonian agent
ATC code	None
Identifiers
IUPAC name 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine
CAS Number	442908-10-3
PubChemCID	21874557
IUPHAR/BPS	5612
DrugBank	DB06625
ChemSpider	10620930
UNII	LDR3USH1NJ
KEGG	D09991
ChEMBL	ChEMBL447664
PDB ligand	9XT (PDBe,RCSB PDB)
CompTox Dashboard(EPA)	DTXSID90196103
Chemical and physical data
Formula	C₁₆H₁₅N₇O
Molar mass	321.344 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N
InChI InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20) Key:HQSBCDPYXDGTCL-UHFFFAOYSA-N

Vipadenant (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name; developmental code nameBIIB014 and others) is anadenosine A_2A receptor antagonist which was under development for the treatment ofParkinson's disease andcancer but was never marketed.^[1]^[2]^[3]^[4] It is takenorally.^[1] The drug was first described in thescientific literature by 2006.^[5]^[6] It was under development byVernalis,Biogen, andJuno Therapeutics.^[1]^[2] Vipadenant reachedphase 2 clinical trials prior to the discontinuation of its development.^[1]^[2]

^^a ^b ^c ^d ^e"Vipadenant".AdisInsight. 28 October 2024. Retrieved28 January 2026.
^^a ^b ^cTerry M (24 January 2026)."Delving into the Latest Updates on Vipadenant with Synapse".Synapse. Retrieved28 January 2026.
^Pinna A (May 2014). "Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued".CNS Drugs.28 (5):455–474.doi:10.1007/s40263-014-0161-7.PMID 24687255.
^Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, et al. (2010). "An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers".Clinical Neuropharmacology.33 (2):55–60.doi:10.1097/WNF.0b013e3181d137d2.PMID 20375654.
^Lightowler, S., Knight, A. R., & Upton, R. (2006). Pharmacology of BIIB014/V2006, an A2A antagonist for the treatment of PD. Targeting Adenosine A2A Receptors in Parkinson’s Disease and Other CNS Disorders. Boston, USA.https://scholar.google.com/scholar?cluster=5861921750099200903
^Gillespie RJ, Bamford SJ, Botting R, Comer M, Denny S, Gaur S, et al. (January 2009). "Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines".Journal of Medicinal Chemistry.52 (1):33–47.doi:10.1021/jm800961g.PMID 19072055.

P2X
(ATPTooltip Adenosine triphosphate)

CNTsTooltip Concentrative nucleoside transporters	6-Hydroxy-7-methoxyflavone Adenosine dMeThPmR Estradiol KGO-2142 KGO-2173 MeThPmR Phloridzin Progesterone
ENTsTooltip Equilibrative nucleoside transporters	Barbiturates Benzodiazepines Cilostazol Dilazep Dipyridamole Estradiol Ethanol Hexobendine NBMPR Pentoxifylline Progesterone Propentofylline
PMATTooltip Plasma membrane monoamine transporter	Decynium-22

XOTooltip Xanthine oxidase	Allopurinol Amflutizole Benzbromarone Caffeic acid Cinnamaldehyde Cinnamomum osmophloeum Febuxostat Myo-inositol Kaempferol Myricetin Niraxostat Oxipurinol Phytic acid Pistacia integerrima Propolis Quercetin Tisopurine Topiroxostat
Others	Aminopterin Azathioprine Methotrexate Mycophenolic acid Pemetrexed Pralatrexate Many others

Others

See also:Receptor/signaling modulators

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information.

Hidden categories: